Inspire Investing LLC Trims Stock Position in United Therapeutics Corporation $UTHR

Inspire Investing LLC trimmed its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 10.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,404 shares of the biotechnology company’s stock after selling 710 shares during the period. Inspire Investing LLC’s holdings in United Therapeutics were worth $1,840,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of UTHR. Chung Wu Investment Group LLC acquired a new stake in United Therapeutics during the 2nd quarter worth $29,000. SVB Wealth LLC acquired a new stake in United Therapeutics during the 1st quarter worth $32,000. Geneos Wealth Management Inc. raised its stake in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares in the last quarter. Sound Income Strategies LLC acquired a new stake in United Therapeutics during the 1st quarter worth $49,000. Finally, Brooklyn Investment Group raised its stake in United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 98 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $450.24, for a total value of $10,130,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 4,000 shares of the firm’s stock in a transaction on Friday, October 10th. The shares were sold at an average price of $444.70, for a total value of $1,778,800.00. Following the completion of the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $57,811. This trade represents a 96.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 261,935 shares of company stock worth $105,561,472 in the last ninety days. 10.30% of the stock is owned by insiders.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $440.00 on Friday. The firm’s fifty day moving average price is $372.27 and its 200 day moving average price is $323.67. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $459.48. The firm has a market cap of $19.85 billion, a price-to-earnings ratio of 17.17, a price-to-earnings-growth ratio of 6.71 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. During the same quarter last year, the business earned $5.85 earnings per share. The business’s quarterly revenue was up 11.7% on a year-over-year basis. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on UTHR shares. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 8th. Morgan Stanley raised their target price on shares of United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a research report on Friday. Oppenheimer raised their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Finally, Royal Bank Of Canada started coverage on shares of United Therapeutics in a research report on Friday, September 26th. They set an “outperform” rating and a $569.00 target price on the stock. Ten equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $457.21.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.